

STARSOURCE MULTITRADE LIMITED
(Formerly known as Chemo Pharma Laboratories Limited)
(CIN: L46900MH1942PLC003556)



Date: May 29, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Subject: Outcome of Board Meeting held on May 29, 2026.

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Friday, May 29, 2026 at the Registered Office of the Company, inter alia, have considered and approved Audited Standalone Financial Results of the Company for the fourth quarter and Year ended March 31, 2026.

In this regards, we are enclosing herewith :

1. Audited Standalone Financial Results of the Company for the fourth quarter and Year ended March 31, 2026, along with Auditors Report thereon.
2. Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid information will also be available on website of the company.

The meeting commenced at 03:30 PM and concluded at 03:45 PM.

The same may please be taken on record.

Thanking You.
Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)

Mehta Ruchit P.



RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India
Corporate Headquarter, 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

Independent Auditor's Report on Quarter and year to date Audited Standalone Financial Results of the company pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Starsource Multitrade Limited
(Formerly Known As Chemo Pharma Laboratories Limited)

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of quarterly and year to date Standalone Financial Results of **STARSOURCE MULTITRADE LIMITED** (the 'Company') for the quarter ended 31st March, 2026 and for the year ended 31st March, 2025 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- I. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- II. gives a true and fair view in conformity with the applicable Indian accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended 31st March, 2026 and for the year ended 31st March, 2026.
- III. As informed to us, only agricultural sales have been recorded in the books of accounts for the relevant period, whereas a higher turnover has been reported in the GST returns. No reconciliation or explanation for the variance has been provided by the management. Further, balance confirmations from various parties were not made available for our verification. Additionally, loss on fair value change in investments booked under indirect expenses is unsupported by adequate explanations or workings. Accordingly, the responsibility for the correctness and completeness of the aforesaid balances, transactions, and disclosures rests solely with the management.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibility for the Standalone financial results

The statement has been prepared on the basis of the standalone annual financial statements.

The Company's Board of Directors is responsible for the preparation and presentation of the statement that give a true and fair view of net profit and other comprehensive loss of the company and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The board of directors are responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our



auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended 31st March, 2026 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For SSRV & Associates

Chartered Accountants

Firm Reg. No. 133801W

Vishnu



Vishnu Kant Kabra

Partner

Membership. No.: 403437

Place: Mumbai

Date: 29th May, 2026

UDIN: 26403437GVQMUD8361

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

Reg Office:- S, Kumud Apartment CHS Limited, Karnik Road Chikan Ghar, Kalyan, Thane, KALYAN, Maharashtra, India, 421301
CIN: L46900MH1942PLC003556 Email: chemopharmalaboratorieslimited@gmail.com, Website: www.starsourcemultitrade.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs. in Thousands, except EPS)

Sr. No.	Particulars	Quarter Ended (Standalone)			Year ended (Standalone)	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		Audited	Un-Audited	Audited	Audited	Audited
1	(a) Net Sales/Income from operations	0.00	0.00	0.00	5,256.56	0.00
	(b) Other Income	8.72	0.00	(1,640.50)	238.86	6,198.43
	Total Income (a+b)	8.72	0.00	(1,640.50)	5495.41	6198.43
2	Expenditure					
	(a) Purchases / Raw Material Consumed	0.00	0.00	0.00	3,765.35	0.00
	(b) Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories	0.00	0.00	0.00	0.00	0.00
	(d) Employee Benefit Expense	216.00	216.00	54.00	888.60	216.00
	(e) Finance Cost	0.00	0.00	0.00	9.81	0.00
	(f) Depreciation & Amortization Expense	3.48	0.00	13.60	3.48	54.48
	(g) Other Expenses	502.20	649.11	129.00	1,19,377.10	947.29
	Total Expenditure (a+b+c+d+e+f+g)	721.69	865.11	196.60	1,24,044.34	1,217.77
3	Profit before Exceptional Items & Tax (1-2)	(712.97)	(865.11)	(1,837.10)	(1,18,548.93)	4,980.66
4	Exceptional Items	0.00	0.00	0.00		0.00
5	Profit before Tax (3-4)	(712.97)	(865.11)	(1,837.10)	(1,18,548.93)	4,980.66
6	Tax Expenses					
	Current Tax					
	(i) Income Tax related to current year	0.00	0.00	1993.29	0.00	1993.26
	(ii) Income Tax of earlier years	0.00	0.00	0.00	0.00	0.00
	(iii) Deferred Tax (Assets)/Liabilities	0.80	0.00	(434.70)	0.80	(434.69)
	(iv) MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00
7	Profit/(loss) after tax for the period (before adjustment for Associate) (5-6)	(713.77)	(865.11)	(3,395.69)	(1,18,549.73)	3,422.09
8	Add : Share of (Profit)/Loss of Associate	0.00	0.00	0.00	0.00	0.00
9	Profit for the Period (after adjustment for Associate (7 + 8))	(713.77)	(865.11)	(3,395.69)	(1,18,549.73)	3,422.09
10	Other Comprehensive Income (OCI)					
	(a) Items not to be reclassified subsequently to profit and loss	0.00	0.00	0.00	0.00	0.00
	(b) Items to be reclassified subsequently to profit and loss	0.00	0.00	0.00	0.00	0.00
	(c) Income Tax Related to item not to be reclassify	0.00	0.00	0.00	0.00	0.00
	(d) Income Tax Related to item to be reclassify	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive Income (9+10)	(713.77)	(865.11)	(3,395.69)	(1,18,549.73)	3,422.09
12	Paid up Equity Share Capital (Face Value Rs. 10/- each)	15,000.00	15,000.00	15,000.00	15,000.00	15,000.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	(2,229.00)	(1,515.23)	1,16,420.39	(2,129.34)	1,16,420.39
14	Earning Per Share (EPS) (par value of Rs. 10/- each)					
	Basic	(0.48)	(0.58)	(2.26)	(79.03)	2.28
	Diluted	(0.48)	(0.58)	(2.26)	(79.03)	2.28
	*Not Annualised					



STANDALONE STATEMENT OF AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2026

Particulars	(Rs. In Thousands)	
	Standalone	
	As at	As at
	31.03.2026	31.03.2025
	Audited	Audited
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	9.65	123.00
(b) Capital Work in Progress	0.00	0.00
(b) Investment properties	60.75	60.70
(c) Other non-current assets/Loans	0.00	25,081.00
(d) Deferred tax assets	0.00	87.88
Total Non Current Assets	70.40	25,352.58
(2) Current assets		
(a) Inventories	0.00	0.00
(b) Financial assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	4,884.39	0.00
(iii) Cash and cash equivalents	122.26	1,06,228.00
(iv) Loans & Deposits	13,040.56	0.00
(v) Other financial assets	0.00	0.00
(c) Current Tax Assets (Net)	0.00	1,917.83
(d) Other current assets	0.00	0.00
Total Current Assets	18,047.21	1,08,145.83
TOTAL ASSETS	18,117.62	1,33,498.41
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	15,000.00	15,000.00
(b) Other equity	-2,103.50	1,16,446.24
Equity attributable to equity holders	12,896.50	1,31,446.24
Total Equity	12,896.50	1,31,446.24
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	0.00	0.00
(b) Deferred tax liabilities	-87.08	0.00
(c) Other Non Current Liabilities	150.00	0.00
Total Non current liabilities	62.92	0.00
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payables		
- Dues of micro enterprises and small enterprises	0.00	0.00
- Dues of creditor other than micro enterprises and small enterprises	4,778.19	0.00
(b) Other Current/Financial Liabilities	0.00	2,052.17
(c) Provisions	300.00	0.00
(d) Income/Current Tax Liabilities (Net)	80.00	0.00
Total Current Liabilities	5,158.19	2,052.17
TOTAL LIABILITIES	5,221.11	2,052.17
TOTAL EQUITY AND LIABILITIES	18,117.62	1,33,498.41



Starsource Multitrade Limited
Statement of Cash Flow for the year ended 31st March, 2026

Particulars	2025-2026	2024-2025
	Rs. in Thousands	Rupees in THOUS
A. Cash Flow From Operating Activities		
Net Profit/(Loss) Before Tax	-118549.73	4980.66
Adjusted for:		
Depreciation & Amortisation	3.48	54.48
Provision for Doubtful Trade Receivables and Advances	0.00	0.00
Reversal of Expected Credit Loss	0.00	0.00
Compensation against Extinguishment of Shares	0.00	0.00
Compensation on Compulsary Acquisition and Damages	0.00	0.00
Net Loss/(Gain) on Sale of Property Plant and Investment.	0.00	0.00
Interest & Finance cost	0.00	0.00
Dividend Income	0.00	-487.12
Interest Income	0.00	-5179.20
Operating profit before working capital changes	-118546.25	-631.18
Adjustments for:		
(Increase)/Decrease of Assets		
Trade and Other receivables	-4884.23	0.00
Inventories	0.00	0.00
Other Non-current/Current assets	1917.83	0.00
Increase/(Decrease) of Liabilities	0.00	0.00
Trade payable / Other Liabilities	5158.90	0.00
(Increase) / Decrease Loans & Deposits	-13040.36	0.00
(Increase) / Decrease Current Assets	0.00	-471.38
(Increase) / Decrease Other Non Current Assets	25081.00	0.00
Increase / (Decrease) Other current liabilities	-1902.17	271.35
Provision Non-current/Current	0.00	0.00
Cash generated from operations	-106215.39	-831.21
Direct Taxes Paid (including for past years)	0.00	-1993.30
NET CASH GENERATED FROM / (USED IN) OPERATING ACTIVITIES (A)	-106215.39	-2824.51
B. Cash flow from investing activities		
Interest Income	0.00	5179.20
Dividend Income	0.00	487.12
Compensation against Extinguishment of Shares	0.00	0.00
Compensation on Compulsary Acquisition and Damages	0.00	0.00
(Purchase) / Sale of Equity shares	109.90	43913.75
Purchase of Property, Plant and Equipment's	0.00	0.00
Movement in Investments/Proceeds from maturity of fixed deposits with banks	-0.05	5500.00
Sale of Property, Plant and Equipment's	0.00	0.00
NET CASH GENERATED FROM / (USED IN) INVESTING ACTIVITIES (B)	109.85	104580.07
C. Cash flow from financing activities		
Inflow		
Increase/(Decrease) in long term borrowing -NET	0.00	0.00
Decrease / (Increase) in Non-current Loans & Advances	0.00	-1585.93
Outflow		
Interest paid	0.00	0.00
NET CASH GENERATED FROM / (USED IN) FINANCING ACTIVITIES (C)	0.00	-1585.93
NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	-106105.54	100169.63
CASH & CASH EQUIVALENTS AS AT THE BEGINNING OF THE YEAR	106227.80	6058.17
CASH & CASH EQUIVALENTS AS AT THE END OF THE YEAR	122.26	106228

Note : The Above Statement of Cash flow has been prepared under the 'Indirect Method' as set out in IND AS 7, Statement of Cash Flow

For S S R V & Associates.

Firm Registration No:135901W

Chartered Accountants

CA Vishnu Kant Kabra

Partner

Membership No :- 403437

Place: Kalyan

Date : 29th May, 2026



For and on behalf of the Board

Meheta Ruchit

Ruchit Mehta
Managing Director
(DIN: 08810586)

STARSOURCE MULTITRADE LIMITED
(Formerly known as Chemo Pharma Laboratories Limited)
(CIN: L46900MH1942PLC003556)



Date: May 29, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Sub: Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read, we do hereby confirm, declare and certify that the financial statements do not contain any false, misleading statements of figures and do not omit material fact which may make the statement or figures contained therein misleading.

You are therefore requested to take on record the aforesaid information for your reference.

Thanking You,
Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)

Mehra Ruchit P.



RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India
Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

STARSOURCE MULTITRADE LIMITED
(Formerly known as Chemo Pharma Laboratories Limited)
(CIN: L46900MH1942PLC003556)



Date: May 29, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Dear Sir/Madam,

Sub: Declaration regarding Auditor's Report with Unmeodified Opinion for the Financial Year ended March 31, 2026 under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI's Circular No. SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare and confirm that Statutory Auditor of the Company M/s. S S R V & Associates (FRN: 135901W), Chartered Accountants have issued Audit Report in respect of Standalone Audited Financial Results for the Financial Year ended on March 31, 2026 with unmodified and unqualified opinion.

Kindly take the same on your records Thanking You.

Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)

Mehta Ruchit R.



RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India
Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

Starsource Multitrade Limited
**RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & YEAR ENDED
 31ST MARCH, 2026**

Rs. In Thousands

PARTICULARS	STANDALONE	
	AUDITED QUARTER ENDED 31.03.2026	AUDITED YEAR ENDED 31.03.2025
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	(412.97)	(1,837.10)
Benefit / (Charge):		
Impact of Deferred Income (Government Grant) Amortized to Income	0.00	0.00
Impact of Fair Valuation of Financial Instruments	0.00	1,993.29
Impact of Actuarial Gain / Loss Taken OCI	0.00	0.00
Impact of Adjustment of Deferred Tax Income	0.00	(434.70)
Impact of Adjustment of MAT Credit Entitlement	0.00	0.00
Net Profit / (Loss) for the Period (as per AS)	(412.97)	(3,395.69)

For Starsource Multitrade Limited



Mehta Ruchit P.

**RUCHIT MEHTA
 MANAGING DIRECTOR
 DIN: 08810586**

Place : Kalyan
 Date : 29th May, 2026

**OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) -
FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2026**

(In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated December 31, 2024)

Sr. No	Particulars	Remarks
1	B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	NOT APPLICABLE
2	C. Format for disclosing outstanding default on loans and debt securities	NOT APPLICABLE
3	D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter)	NOT APPLICABLE
4	E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	NOT APPLICABLE

FOR STARSOURCE MULTITRADE LIMITED



Mehta Ruchit P.

Date : 29th May, 2026
Place : Kalyan

RUCHIT MEHTA
MD & CEO
DIN: 08810586